InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,599.60
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.37
(
-0.13%
)
Bitcoin
63,851.01
(
1.09%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 8871

Saturday, 03/15/2008 6:12:36 PM

Saturday, March 15, 2008 6:12:36 PM

Post# of 19309
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up